This study is testing a new treatment called **EYP-1901** for **wet Age-Related Macular Degeneration** (**wAMD**), a serious eye condition causing vision loss. Researchers will check how well EYP-1901 works compared to another drug, **Aflibercept**. This is a **phase 3** study, meaning it's one of the last steps before the treatment can be approved for everyone. It's a **randomized** and **double-masked** study, meaning neither the participants nor the researchers know who is getting which treatment to ensure fairness.

Key Points:

• The study will last for **2 years**, with primary results checked at **week 56**.
• To join, you should have or had wAMD, and if treated before, received at least 2 injections in the past 6 months.
• Some people can't join if they have specific conditions like scarring in certain parts of their eye or very low vision in the other eye.

This study might involve several visits and tests. Before joining, ensure you understand the risks and benefits, and discuss with your doctor. Participants may receive compensation for their time and expenses related to the study.